Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic study helps patients with pancreatic cancer experience significantly less pain

03.03.2004


The intense pain many patients with pancreatic cancer experience may be reduced by more than 50 percent using a nerve block technique along with the standard pain-relieving medications. That is the finding of a Mayo Clinic study that will be published in the March 3 edition of the Journal of the American Medical Association (JAMA).



The study also found that the neurolytic celiac plexus block (NCPB), the type of nerve block used, continued to provide sustained pain relief over several months. This benefit may allow some patients with advanced pancreatic cancer to live more comfortably for the duration of their lives.

The Mayo Clinic study is the largest research study to date on managing pain in patients with pancreatic cancer, using the NCPB technique along with pain-relieving medications compared to pain-relieving medications alone. The study was led by Gilbert Wong, M.D., a Mayo Clinic anesthesiologist specializing in pain medicine, who also heads the Mayo Clinic Cancer Center’s Psychosocial Oncology Group.


"The pain caused by pancreatic cancer ranks among the most horrible pains anyone can experience or imagine," says Dr. Wong. "Previous research studies have suggested that 85 percent of patients with advanced disease can experience significant pain."

Pancreatic cancer is an aggressive tumor associated with a high mortality. This year an estimated 31,000 people in the United States will be diagnosed with pancreatic cancer and the majority of them will die within a year.

The Mayo Clinic study involved 100 patients who had advanced pancreatic cancer that could not be surgically removed, and were experiencing significant pain. The patients were randomly assigned to receive either the NCPB or potent pain-relieving medications alone, such as morphine, which is typical treatment for cancer pain. Subsequently, all patients could receive additional pain-relieving medications as needed. All of the patients were followed until death or for at least one year after enrolling in the study.

"Pain-relieving medications alone provided the patients with a 27 percent reduction in pain," Dr. Wong says. "Our goal was to find a better way to further reduce the pain and thereby help them live their remaining time more comfortably.

"We found that patients who also received the NCPB reported a greater than 50 percent reduction in their pain, almost twice the relief that patients who received only the pain-relieving medications got," says Dr. Wong. "Equally as important, we found that the pain relief from the combination of nerve block and pain-relieving medications lasted longer, helping some patients for the duration of their illness."

Pancreatic cancer often shows no warning signs until the tumor has grown to the point that it cannot be surgically removed. Then, approximately 80 percent of patients begin to have significant pain in the upper abdomen and mid-back. By that time, however, the cancer is often advanced and the average survival time is about six months.

"The findings of our study suggest the nerve block technique works for a substantial number of patients with advanced pancreatic cancer and should be considered as a treatment option," says Dr. Wong. "It’s an important benefit to patients with pancreatic cancer and important information for physicians who take care of them."

Study Details

One hundred patients with nonresectable pancreatic cancer and experiencing significant pain were enrolled between October 1997 and January 2001 and followed until demise or at least one year. Baseline pain was similar among patients assigned to receive the NCPB and those receiving systemic analgesic therapy (SAT) alone.

In the first week of treatment, patients in both groups reported less intense pain and improved quality of life, but patients receiving the NCPB had a larger decrease in pain than patients receiving SAT. At six weeks, fewer patients receiving the NCPB reported moderate or severe pain compared to SAT patients. Repeated analysis through the first six months after enrolling in the study showed NCPB patients had significantly lower pain over time than SAT patients. However, consumption of opioids and frequency of opioid side effects, such as sleepiness, nausea and constipation, were not significantly different between the two groups.

One year after enrolling in the study, 16 percent of patients receiving the NCPB and six percent of SAT patients were still alive.


The Mayo Clinic study, titled "Effects of Neurolytic Celiac Plexus Block on Pain Relief, Quality of Life and Survival in Patients with Unresectable Pancreatic Cancer," was funded with grants from FAER -- Foundation for Anesthesia, Education and Research, Cancer Treatment Research Foundation, and the Ehlers Family for Psychosocial Oncology and Spiritual Care Research at the Mayo Clinic Cancer Center.

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories

Mary Lawson | EurekAlert!
Further information:
http://www.mayoclinic.org/news
http://www.mayoclinic.com

More articles from Health and Medicine:

nachricht Penn studies find promise for innovations in liquid biopsies
30.03.2017 | University of Pennsylvania School of Medicine

nachricht 'On-off switch' brings researchers a step closer to potential HIV vaccine
30.03.2017 | University of Nebraska-Lincoln

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

'On-off switch' brings researchers a step closer to potential HIV vaccine

30.03.2017 | Health and Medicine

Penn studies find promise for innovations in liquid biopsies

30.03.2017 | Health and Medicine

An LED-based device for imaging radiation induced skin damage

30.03.2017 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>